In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 34127-22-5, name is Ethyl 3,6-dichloropyridazine-4-carboxylate, introducing its new discovery. Application In Synthesis of Ethyl 3,6-dichloropyridazine-4-carboxylate
PYRIDAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS
The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3, each R1 group has any of the meanings defined in the description, Rais halogeno or (1-6C)alkoxy, Rb is halogeno or (1-6C)alkoxy, and Rcis hydrogen, halogeno, (1-8C)alkyl or (1-6C)alkoxy, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 34127-22-5, and how the biochemistry of the body works.Application In Synthesis of Ethyl 3,6-dichloropyridazine-4-carboxylate
Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2953 – PubChem